Safety and Efficacy of FAP iCDC in Ischemia Cardiomyopathy

NCT07505199 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Ischemic Cardiomyopathy
Cell Therapy

Interventions

BIOLOGICAL: autologus FAP-targeted immunosuppressive CAR-DCs (iCDC)

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University